Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar Health, Inc.) on December 15, 2016. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to seven members.
- New Director Appointment: Dr. Ari Azhir was appointed as a Class I director, serving until the 2019 annual meeting.
- Committee Assignments: Dr. Azhir was appointed to the Audit Committee, Compensation Committee, and Nominating Committee.
- Compensation Grant: Dr. Azhir was granted options to purchase 98,050 shares of common stock under the 2014 Stock Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. The document notes that Dr. Azhir brings extensive experience in CNS therapeutics, drug development, and commercialization, having successfully brought over 20 healthcare products to market.
Investor Verification Checklist
- Verify the vesting schedule of the 98,050 stock options granted to Dr. Azhir (monthly vesting over 3 years).
- Confirm the exercise price of the granted options is $0.74 per share.
- Review the updated composition of the Audit, Compensation, and Nominating Committees.
- Check the press release dated December 19, 2016 (Exhibit 99.1) for additional context on the appointment.